Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Baillie Gifford -International All Cap. This analysis is provided for institutional research purposes only and is not investment advice.
"Baillie Gifford's International All Cap underperformed in Q1 as European defense and banking sectors rallied, areas where the growth-focused strategy has minimal exposure. However, cyclical recovery is emerging across industrials, healthcare, and semiconductors while Chinese stimulus creates global growth opportunities."
Baillie Gifford's International All Cap strategy underperformed in Q1 2025 as European markets rallied strongly, driven by defense and banking sectors where the fund maintains minimal exposure. As growth investors, the managers avoid traditional banks due to poor returns on capital, though they have selectively added UBS and SEB where differentiated growth opportunities exist. The strategy benefits from emerging cyclical recovery across industrials, healthcare, and semiconductors, with companies like Sartorius, ASML, Tokyo Electron, and TSMC showing positive momentum. Chinese stimulus measures over the past six months, including renewed support for private entrepreneurs symbolized by Xi Jinping's technology meetings, create opportunities for both domestic Chinese holdings and global companies exposed to Chinese growth like BHP and SMC. The fund added three new holdings during the quarter - UBS, Spirax, and Roche - all representing underappreciated growth stories trading at attractive valuations. Despite near-term underperformance, the managers remain decidedly optimistic about growth acceleration potential across their portfolio, focusing on companies that can deliver both earnings growth and multiple expansion.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
The fund operates a diversified strategy (with multiple variants including ACWI ex US All Cap, EAFE Plus, and Developed EAFE All Cap) with a wide array of holdings. While the managers present clear, logical arguments for new holdings like UBS and Roche, they also acknowledge the difficulty of building bottom-up conviction in sectors like defense due to political and technical uncertainties, choosing to stay out completely.
Growth Outlook
The managers are moderately optimistic (constructive) about international equity markets, noting that non-US equities have performed very strongly and outperformed their US counterparts. They highlight signs of broadening optimism in Europe and cyclical recovery in semiconductor supply chains, industrials, and healthcare, alongside a positive pivot in China's economic policy.
Risk Appetite
The managers maintain a growth-focused, risk-tolerant posture, actively adding new holdings in undervalued and cyclically depressed growth areas (e.g., Roche, Spirax). They are selectively expanding into previously avoided areas like banks (SEB, UBS) to capture unique growth, indicating a willingness to adapt without taking on excessive value-based risk.
Capital Deployment
Capital deployment is moderately high. The managers added three new holdings over the quarter (UBS, Spirax, and Roche) and increased exposure to selected banks (SEB, UBS). This indicates active redeployment of capital into newly discovered growth ideas.
Forward Guidance
The fund exhibits an active deployment bias, having established three new major holdings (UBS, Spirax, Roche) during the quarter. They articulate a clear playbook of buying high-quality growth businesses during temporary operational lulls to benefit from both fundamental acceleration and multiple re-ratings.
Language Signal
The tone is predominantly positive, with frequent references to 'growth acceleration,' 'really exciting,' 'positive guidance,' and 'decidedly optimistic.' While they discuss the challenges of the defense sector and past underperformance, the language tilts heavily toward identifying mispriced, high-upside opportunities.
Perceived Risk
The managers discuss standard macro risks, including tariffs, trade restrictions, and geopolitical tensions. However, they express high confidence that the best management teams can easily navigate these hurdles (e.g., TSMC's successful US expansion), viewing risks more as structural change that creates opportunities rather than threats of a systemic market crash.
Opportunity Density
The managers see a rich opportunity set arising from structural shifts, a cyclical recovery across multiple industries, and Chinese policy stimulus. They describe several exciting areas—healthcare restocking, semiconductor supply chains, industrial automation, and mispriced healthcare stocks—stating they are 'feeling decidedly optimistic.'
Time Horizon
The managers explicitly emphasize 'thinking long-term' and investing in companies that can sustain growth over multi-year cycles. They cite examples like TSMC's decade-long transition to US manufacturing to illustrate their long-term focus, showing zero interest in short-term trading.
